Global NewsNews

BARDA, Clarivate partner to identify therapeutics during health emergencies

BARDA funding will aid in target identification and drug factor analyses to identify potential drugs for repurposing to treat chemical agent exposure

Clarivate, a global leader in providing trusted information and insights to accelerate the pace of innovation, announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), which provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. 

The new collaboration will leverage Clarivate Consulting Service’s computational approach in identifying therapeutics for potential repurposing as medical countermeasures (MCMs) against chlorine and sulfur mustard induced injuries.

Drug repurposing evaluates new uses, outside of the original clinical indication, for therapeutics approved by the US Food and Drug Administration (FDA) or in late-stage development. BARDA funding will aid in target identification and drug factor analyses to identify potential drugs for repurposing to treat chemical agent exposure. These drugs may affect biological pathways that are implicated in chemical agent exposure or the body’s response to it and may already treat analogous diseases with similar biology but different causes. Such drugs, particularly when highly available in our pharmaceutical supply chain, maybe studied and developed in an accelerated manner to provide reserve capacity in response to exposure events.

Clarivate will identify drugs that are commonly available and can be used as MCMs for exposure to chemical agents. The Clarivate suite of research intelligence solutions used in the project will include MetaBase, Cortellis Drug Discovery Intelligence, OFF-X, and real-world data featured within the Clarivate Research Intelligence Cloud. Paired with deep domain expertise, Clarivate will evaluate genomic experiments, systems and computational biology, as well as known protein-protein interactions and molecular pathways accessed through its proprietary curated databases. This approach is expected to provide a fast, focused method for screening drug candidates most likely to be repurposed successfully for treating chemical exposures.

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close